nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Cytarabine—Gemcitabine—kidney cancer	0.371	0.513	CrCrCtD
Regadenoson—Azacitidine—Gemcitabine—kidney cancer	0.353	0.487	CrCrCtD
Regadenoson—Adenosine triphosphate—APAF1—kidney cancer	0.00303	0.468	CrCbGaD
Regadenoson—Adenosine monophosphate—APRT—kidney cancer	0.00225	0.348	CrCbGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—VHL—kidney cancer	0.00113	0.0879	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—EPAS1—kidney cancer	0.00113	0.0879	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—PGK1—kidney cancer	0.00108	0.0842	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—ALK—kidney cancer	0.00105	0.163	CrCbGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—TCEB1—kidney cancer	0.000989	0.077	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—TCEB2—kidney cancer	0.000989	0.077	CbGpPWpGaD
Regadenoson—ADORA2A—Monoamine Transport—ACHE—kidney cancer	0.000695	0.0542	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—FLT1—kidney cancer	0.00059	0.046	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—SLC2A1—kidney cancer	0.000551	0.0429	CbGpPWpGaD
Regadenoson—ADORA2A—Monoamine Transport—TSC2—kidney cancer	0.000372	0.029	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—KDR—kidney cancer	0.00034	0.0265	CbGpPWpGaD
Regadenoson—Diarrhoea—Vinblastine—kidney cancer	0.000236	0.00092	CcSEcCtD
Regadenoson—Abdominal pain—Sorafenib—kidney cancer	0.000236	0.000919	CcSEcCtD
Regadenoson—Diarrhoea—Everolimus—kidney cancer	0.000235	0.000916	CcSEcCtD
Regadenoson—Gastrointestinal pain—Sunitinib—kidney cancer	0.000235	0.000915	CcSEcCtD
Regadenoson—Hyperhidrosis—Vincristine—kidney cancer	0.000235	0.000915	CcSEcCtD
Regadenoson—Pain—Dactinomycin—kidney cancer	0.000233	0.000906	CcSEcCtD
Regadenoson—Dysgeusia—Paclitaxel—kidney cancer	0.000232	0.000902	CcSEcCtD
Regadenoson—Anaphylactic shock—Gemcitabine—kidney cancer	0.000231	0.000898	CcSEcCtD
Regadenoson—Eye pain—Doxorubicin—kidney cancer	0.00023	0.000896	CcSEcCtD
Regadenoson—Dizziness—Vinblastine—kidney cancer	0.000228	0.000889	CcSEcCtD
Regadenoson—Dizziness—Everolimus—kidney cancer	0.000227	0.000886	CcSEcCtD
Regadenoson—Abdominal pain—Sunitinib—kidney cancer	0.000227	0.000884	CcSEcCtD
Regadenoson—Diarrhoea—Erlotinib—kidney cancer	0.000227	0.000884	CcSEcCtD
Regadenoson—Hypotension—Vincristine—kidney cancer	0.000227	0.000884	CcSEcCtD
Regadenoson—Bradycardia—Capecitabine—kidney cancer	0.000227	0.000884	CcSEcCtD
Regadenoson—Nervous system disorder—Gemcitabine—kidney cancer	0.000226	0.00088	CcSEcCtD
Regadenoson—Feeling abnormal—Dactinomycin—kidney cancer	0.000224	0.000873	CcSEcCtD
Regadenoson—Skin disorder—Gemcitabine—kidney cancer	0.000224	0.000872	CcSEcCtD
Regadenoson—Vision blurred—Paclitaxel—kidney cancer	0.000223	0.000868	CcSEcCtD
Regadenoson—Hyperhidrosis—Gemcitabine—kidney cancer	0.000223	0.000868	CcSEcCtD
Regadenoson—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000222	0.000866	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—HNF1B—kidney cancer	0.000222	0.0173	CbGpPWpGaD
Regadenoson—Hypoaesthesia—Capecitabine—kidney cancer	0.000222	0.000864	CcSEcCtD
Regadenoson—Tremor—Paclitaxel—kidney cancer	0.000222	0.000863	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000221	0.000862	CcSEcCtD
Regadenoson—Hypersensitivity—Sorafenib—kidney cancer	0.00022	0.000856	CcSEcCtD
Regadenoson—Insomnia—Vincristine—kidney cancer	0.00022	0.000856	CcSEcCtD
Regadenoson—Vomiting—Vinblastine—kidney cancer	0.00022	0.000855	CcSEcCtD
Regadenoson—Dizziness—Erlotinib—kidney cancer	0.000219	0.000854	CcSEcCtD
Regadenoson—Ill-defined disorder—Paclitaxel—kidney cancer	0.000219	0.000854	CcSEcCtD
Regadenoson—Connective tissue disorder—Capecitabine—kidney cancer	0.000219	0.000853	CcSEcCtD
Regadenoson—Vomiting—Everolimus—kidney cancer	0.000219	0.000851	CcSEcCtD
Regadenoson—Renal impairment—Doxorubicin—kidney cancer	0.000218	0.00085	CcSEcCtD
Regadenoson—Paraesthesia—Vincristine—kidney cancer	0.000218	0.00085	CcSEcCtD
Regadenoson—Rash—Everolimus—kidney cancer	0.000217	0.000844	CcSEcCtD
Regadenoson—Dermatitis—Everolimus—kidney cancer	0.000217	0.000844	CcSEcCtD
Regadenoson—Headache—Vinblastine—kidney cancer	0.000216	0.000842	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—KCNMA1—kidney cancer	0.000216	0.0168	CbGpPWpGaD
Regadenoson—Angioedema—Paclitaxel—kidney cancer	0.000216	0.000841	CcSEcCtD
Regadenoson—Headache—Everolimus—kidney cancer	0.000215	0.000839	CcSEcCtD
Regadenoson—Hypotension—Gemcitabine—kidney cancer	0.000215	0.000839	CcSEcCtD
Regadenoson—Abdominal pain—Dactinomycin—kidney cancer	0.000215	0.000837	CcSEcCtD
Regadenoson—Asthenia—Sorafenib—kidney cancer	0.000214	0.000834	CcSEcCtD
Regadenoson—Malaise—Paclitaxel—kidney cancer	0.000213	0.00083	CcSEcCtD
Regadenoson—Syncope—Paclitaxel—kidney cancer	0.000212	0.000826	CcSEcCtD
Regadenoson—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000212	0.000825	CcSEcCtD
Regadenoson—Hypersensitivity—Sunitinib—kidney cancer	0.000212	0.000824	CcSEcCtD
Regadenoson—Vomiting—Erlotinib—kidney cancer	0.000211	0.000822	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.00021	0.000818	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Vincristine—kidney cancer	0.00021	0.000817	CcSEcCtD
Regadenoson—Rash—Erlotinib—kidney cancer	0.000209	0.000815	CcSEcCtD
Regadenoson—Dermatitis—Erlotinib—kidney cancer	0.000209	0.000814	CcSEcCtD
Regadenoson—Palpitations—Paclitaxel—kidney cancer	0.000209	0.000814	CcSEcCtD
Regadenoson—Insomnia—Gemcitabine—kidney cancer	0.000209	0.000812	CcSEcCtD
Regadenoson—Eye disorder—Capecitabine—kidney cancer	0.000208	0.000811	CcSEcCtD
Regadenoson—Headache—Erlotinib—kidney cancer	0.000208	0.000809	CcSEcCtD
Regadenoson—Tinnitus—Capecitabine—kidney cancer	0.000208	0.000809	CcSEcCtD
Regadenoson—Loss of consciousness—Paclitaxel—kidney cancer	0.000208	0.000809	CcSEcCtD
Regadenoson—Pain—Vincristine—kidney cancer	0.000208	0.000809	CcSEcCtD
Regadenoson—Pain in extremity—Doxorubicin—kidney cancer	0.000208	0.000809	CcSEcCtD
Regadenoson—Paraesthesia—Gemcitabine—kidney cancer	0.000207	0.000806	CcSEcCtD
Regadenoson—Cardiac disorder—Capecitabine—kidney cancer	0.000207	0.000806	CcSEcCtD
Regadenoson—Flushing—Capecitabine—kidney cancer	0.000207	0.000806	CcSEcCtD
Regadenoson—Cough—Paclitaxel—kidney cancer	0.000206	0.000803	CcSEcCtD
Regadenoson—Asthenia—Sunitinib—kidney cancer	0.000206	0.000803	CcSEcCtD
Regadenoson—Dyspnoea—Gemcitabine—kidney cancer	0.000206	0.0008	CcSEcCtD
Regadenoson—Nausea—Vinblastine—kidney cancer	0.000205	0.000799	CcSEcCtD
Regadenoson—Somnolence—Gemcitabine—kidney cancer	0.000205	0.000798	CcSEcCtD
Regadenoson—Convulsion—Paclitaxel—kidney cancer	0.000205	0.000798	CcSEcCtD
Regadenoson—Nausea—Everolimus—kidney cancer	0.000204	0.000795	CcSEcCtD
Regadenoson—Diarrhoea—Sorafenib—kidney cancer	0.000204	0.000795	CcSEcCtD
Regadenoson—Hypertension—Paclitaxel—kidney cancer	0.000204	0.000795	CcSEcCtD
Regadenoson—Angiopathy—Capecitabine—kidney cancer	0.000202	0.000788	CcSEcCtD
Regadenoson—Immune system disorder—Capecitabine—kidney cancer	0.000201	0.000784	CcSEcCtD
Regadenoson—Arthralgia—Paclitaxel—kidney cancer	0.000201	0.000784	CcSEcCtD
Regadenoson—Myalgia—Paclitaxel—kidney cancer	0.000201	0.000784	CcSEcCtD
Regadenoson—Chest pain—Paclitaxel—kidney cancer	0.000201	0.000784	CcSEcCtD
Regadenoson—Mediastinal disorder—Capecitabine—kidney cancer	0.000201	0.000782	CcSEcCtD
Regadenoson—Anxiety—Paclitaxel—kidney cancer	0.000201	0.000781	CcSEcCtD
Regadenoson—Hypersensitivity—Dactinomycin—kidney cancer	0.0002	0.00078	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.0002	0.000778	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000199	0.000775	CcSEcCtD
Regadenoson—Discomfort—Paclitaxel—kidney cancer	0.000199	0.000774	CcSEcCtD
Regadenoson—Gastrointestinal pain—Vincristine—kidney cancer	0.000199	0.000774	CcSEcCtD
Regadenoson—Cardiac arrest—Doxorubicin—kidney cancer	0.000198	0.000769	CcSEcCtD
Regadenoson—Dizziness—Sorafenib—kidney cancer	0.000197	0.000769	CcSEcCtD
Regadenoson—Pain—Gemcitabine—kidney cancer	0.000197	0.000768	CcSEcCtD
Regadenoson—Nausea—Erlotinib—kidney cancer	0.000197	0.000768	CcSEcCtD
Regadenoson—Diarrhoea—Sunitinib—kidney cancer	0.000197	0.000765	CcSEcCtD
Regadenoson—Mental disorder—Capecitabine—kidney cancer	0.000195	0.00076	CcSEcCtD
Regadenoson—Asthenia—Dactinomycin—kidney cancer	0.000195	0.00076	CcSEcCtD
Regadenoson—Erythema—Capecitabine—kidney cancer	0.000194	0.000756	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—JUND—kidney cancer	0.000194	0.0151	CbGpPWpGaD
Regadenoson—Anaphylactic shock—Paclitaxel—kidney cancer	0.000193	0.000751	CcSEcCtD
Regadenoson—Abdominal pain—Vincristine—kidney cancer	0.000192	0.000748	CcSEcCtD
Regadenoson—Dysgeusia—Capecitabine—kidney cancer	0.00019	0.00074	CcSEcCtD
Regadenoson—Dizziness—Sunitinib—kidney cancer	0.00019	0.00074	CcSEcCtD
Regadenoson—Feeling abnormal—Gemcitabine—kidney cancer	0.00019	0.00074	CcSEcCtD
Regadenoson—Shock—Paclitaxel—kidney cancer	0.00019	0.000739	CcSEcCtD
Regadenoson—Vomiting—Sorafenib—kidney cancer	0.00019	0.000739	CcSEcCtD
Regadenoson—Nervous system disorder—Paclitaxel—kidney cancer	0.000189	0.000737	CcSEcCtD
Regadenoson—Tachycardia—Paclitaxel—kidney cancer	0.000188	0.000733	CcSEcCtD
Regadenoson—Rash—Sorafenib—kidney cancer	0.000188	0.000733	CcSEcCtD
Regadenoson—Dermatitis—Sorafenib—kidney cancer	0.000188	0.000732	CcSEcCtD
Regadenoson—Skin disorder—Paclitaxel—kidney cancer	0.000187	0.00073	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—kidney cancer	0.000187	0.0146	CbGpPWpGaD
Regadenoson—Headache—Sorafenib—kidney cancer	0.000187	0.000728	CcSEcCtD
Regadenoson—Hyperhidrosis—Paclitaxel—kidney cancer	0.000187	0.000726	CcSEcCtD
Regadenoson—Diarrhoea—Dactinomycin—kidney cancer	0.000186	0.000725	CcSEcCtD
Regadenoson—Vision blurred—Capecitabine—kidney cancer	0.000183	0.000712	CcSEcCtD
Regadenoson—Vomiting—Sunitinib—kidney cancer	0.000183	0.000711	CcSEcCtD
Regadenoson—Tremor—Capecitabine—kidney cancer	0.000182	0.000708	CcSEcCtD
Regadenoson—Rash—Sunitinib—kidney cancer	0.000181	0.000705	CcSEcCtD
Regadenoson—Dermatitis—Sunitinib—kidney cancer	0.000181	0.000705	CcSEcCtD
Regadenoson—Abdominal distension—Doxorubicin—kidney cancer	0.000181	0.000704	CcSEcCtD
Regadenoson—Hypotension—Paclitaxel—kidney cancer	0.00018	0.000702	CcSEcCtD
Regadenoson—Ill-defined disorder—Capecitabine—kidney cancer	0.00018	0.000701	CcSEcCtD
Regadenoson—Headache—Sunitinib—kidney cancer	0.00018	0.000701	CcSEcCtD
Regadenoson—Asthma—Doxorubicin—kidney cancer	0.00018	0.000699	CcSEcCtD
Regadenoson—Hypersensitivity—Vincristine—kidney cancer	0.000179	0.000697	CcSEcCtD
Regadenoson—Nausea—Sorafenib—kidney cancer	0.000177	0.00069	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000176	0.000685	CcSEcCtD
Regadenoson—Malaise—Capecitabine—kidney cancer	0.000175	0.000681	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—kidney cancer	0.000175	0.000681	CcSEcCtD
Regadenoson—Insomnia—Paclitaxel—kidney cancer	0.000175	0.00068	CcSEcCtD
Regadenoson—Asthenia—Vincristine—kidney cancer	0.000174	0.000679	CcSEcCtD
Regadenoson—Syncope—Capecitabine—kidney cancer	0.000174	0.000678	CcSEcCtD
Regadenoson—Paraesthesia—Paclitaxel—kidney cancer	0.000173	0.000675	CcSEcCtD
Regadenoson—Vomiting—Dactinomycin—kidney cancer	0.000173	0.000673	CcSEcCtD
Regadenoson—Dyspnoea—Paclitaxel—kidney cancer	0.000172	0.00067	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ITPR2—kidney cancer	0.000172	0.0134	CbGpPWpGaD
Regadenoson—Somnolence—Paclitaxel—kidney cancer	0.000172	0.000668	CcSEcCtD
Regadenoson—Palpitations—Capecitabine—kidney cancer	0.000172	0.000668	CcSEcCtD
Regadenoson—Rash—Dactinomycin—kidney cancer	0.000171	0.000668	CcSEcCtD
Regadenoson—Nausea—Sunitinib—kidney cancer	0.000171	0.000664	CcSEcCtD
Regadenoson—Loss of consciousness—Capecitabine—kidney cancer	0.000171	0.000664	CcSEcCtD
Regadenoson—Cough—Capecitabine—kidney cancer	0.000169	0.000659	CcSEcCtD
Regadenoson—Hypertension—Capecitabine—kidney cancer	0.000168	0.000652	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000167	0.000649	CcSEcCtD
Regadenoson—Diarrhoea—Vincristine—kidney cancer	0.000166	0.000647	CcSEcCtD
Regadenoson—Asthenia—Gemcitabine—kidney cancer	0.000165	0.000644	CcSEcCtD
Regadenoson—Chest pain—Capecitabine—kidney cancer	0.000165	0.000643	CcSEcCtD
Regadenoson—Myalgia—Capecitabine—kidney cancer	0.000165	0.000643	CcSEcCtD
Regadenoson—Arthralgia—Capecitabine—kidney cancer	0.000165	0.000643	CcSEcCtD
Regadenoson—Pain—Paclitaxel—kidney cancer	0.000165	0.000643	CcSEcCtD
Regadenoson—Anxiety—Capecitabine—kidney cancer	0.000165	0.000641	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000164	0.000639	CcSEcCtD
Regadenoson—Discomfort—Capecitabine—kidney cancer	0.000163	0.000636	CcSEcCtD
Regadenoson—Nausea—Dactinomycin—kidney cancer	0.000162	0.000629	CcSEcCtD
Regadenoson—Dizziness—Vincristine—kidney cancer	0.000161	0.000626	CcSEcCtD
Regadenoson—Feeling abnormal—Paclitaxel—kidney cancer	0.000159	0.000619	CcSEcCtD
Regadenoson—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000158	0.000614	CcSEcCtD
Regadenoson—Diarrhoea—Gemcitabine—kidney cancer	0.000158	0.000614	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—kidney cancer	0.000157	0.000613	CcSEcCtD
Regadenoson—Shock—Capecitabine—kidney cancer	0.000156	0.000607	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—AKAP13—kidney cancer	0.000156	0.0121	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CASP2—kidney cancer	0.000156	0.0121	CbGpPWpGaD
Regadenoson—Nervous system disorder—Capecitabine—kidney cancer	0.000155	0.000605	CcSEcCtD
Regadenoson—Tachycardia—Capecitabine—kidney cancer	0.000155	0.000602	CcSEcCtD
Regadenoson—Vomiting—Vincristine—kidney cancer	0.000155	0.000602	CcSEcCtD
Regadenoson—Skin disorder—Capecitabine—kidney cancer	0.000154	0.000599	CcSEcCtD
Regadenoson—Urticaria—Paclitaxel—kidney cancer	0.000153	0.000597	CcSEcCtD
Regadenoson—Rash—Vincristine—kidney cancer	0.000153	0.000597	CcSEcCtD
Regadenoson—Hyperhidrosis—Capecitabine—kidney cancer	0.000153	0.000596	CcSEcCtD
Regadenoson—Dermatitis—Vincristine—kidney cancer	0.000153	0.000596	CcSEcCtD
Regadenoson—Abdominal pain—Paclitaxel—kidney cancer	0.000153	0.000594	CcSEcCtD
Regadenoson—Headache—Vincristine—kidney cancer	0.000152	0.000593	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—OR4C13—kidney cancer	0.00015	0.0117	CbGpPWpGaD
Regadenoson—Hypotension—Capecitabine—kidney cancer	0.000148	0.000576	CcSEcCtD
Regadenoson—Vomiting—Gemcitabine—kidney cancer	0.000147	0.000571	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—kidney cancer	0.000146	0.00057	CcSEcCtD
Regadenoson—Rash—Gemcitabine—kidney cancer	0.000145	0.000566	CcSEcCtD
Regadenoson—Dermatitis—Gemcitabine—kidney cancer	0.000145	0.000565	CcSEcCtD
Regadenoson—Headache—Gemcitabine—kidney cancer	0.000144	0.000562	CcSEcCtD
Regadenoson—Nausea—Vincristine—kidney cancer	0.000144	0.000562	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000144	0.000562	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABCB1—kidney cancer	0.000144	0.0222	CrCbGaD
Regadenoson—Insomnia—Capecitabine—kidney cancer	0.000143	0.000558	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—kidney cancer	0.000143	0.000557	CcSEcCtD
Regadenoson—Paraesthesia—Capecitabine—kidney cancer	0.000142	0.000554	CcSEcCtD
Regadenoson—Hypersensitivity—Paclitaxel—kidney cancer	0.000142	0.000554	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—kidney cancer	0.000141	0.00055	CcSEcCtD
Regadenoson—Dyspnoea—Capecitabine—kidney cancer	0.000141	0.00055	CcSEcCtD
Regadenoson—Asthenia—Paclitaxel—kidney cancer	0.000138	0.000539	CcSEcCtD
Regadenoson—Nausea—Gemcitabine—kidney cancer	0.000137	0.000533	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000137	0.000532	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—OR4C13—kidney cancer	0.000136	0.0106	CbGpPWpGaD
Regadenoson—Pain—Capecitabine—kidney cancer	0.000135	0.000527	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—kidney cancer	0.000134	0.000523	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—kidney cancer	0.000134	0.000522	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—kidney cancer	0.000133	0.000519	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—kidney cancer	0.000133	0.000519	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—ITPR2—kidney cancer	0.000132	0.0103	CbGpPWpGaD
Regadenoson—Diarrhoea—Paclitaxel—kidney cancer	0.000132	0.000514	CcSEcCtD
Regadenoson—Feeling abnormal—Capecitabine—kidney cancer	0.000131	0.000508	CcSEcCtD
Regadenoson—Angiopathy—Doxorubicin—kidney cancer	0.00013	0.000508	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—kidney cancer	0.00013	0.000505	CcSEcCtD
Regadenoson—Gastrointestinal pain—Capecitabine—kidney cancer	0.00013	0.000504	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—kidney cancer	0.00013	0.000504	CcSEcCtD
Regadenoson—Dizziness—Paclitaxel—kidney cancer	0.000128	0.000497	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—kidney cancer	0.000126	0.00049	CcSEcCtD
Regadenoson—Urticaria—Capecitabine—kidney cancer	0.000126	0.00049	CcSEcCtD
Regadenoson—Abdominal pain—Capecitabine—kidney cancer	0.000125	0.000487	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—kidney cancer	0.000125	0.000487	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—EGR1—kidney cancer	0.000123	0.00962	CbGpPWpGaD
Regadenoson—Vomiting—Paclitaxel—kidney cancer	0.000123	0.000478	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—kidney cancer	0.000123	0.000477	CcSEcCtD
Regadenoson—Rash—Paclitaxel—kidney cancer	0.000122	0.000474	CcSEcCtD
Regadenoson—Dermatitis—Paclitaxel—kidney cancer	0.000122	0.000473	CcSEcCtD
Regadenoson—Headache—Paclitaxel—kidney cancer	0.000121	0.000471	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—kidney cancer	0.000118	0.000459	CcSEcCtD
Regadenoson—Hypersensitivity—Capecitabine—kidney cancer	0.000117	0.000454	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—kidney cancer	0.000116	0.000452	CcSEcCtD
Regadenoson—Nausea—Paclitaxel—kidney cancer	0.000115	0.000446	CcSEcCtD
Regadenoson—Asthenia—Capecitabine—kidney cancer	0.000114	0.000442	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—kidney cancer	0.000113	0.000439	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—kidney cancer	0.000112	0.000437	CcSEcCtD
Regadenoson—Palpitations—Doxorubicin—kidney cancer	0.000111	0.00043	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—kidney cancer	0.00011	0.000428	CcSEcCtD
Regadenoson—Cough—Doxorubicin—kidney cancer	0.000109	0.000425	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—kidney cancer	0.000108	0.000422	CcSEcCtD
Regadenoson—Diarrhoea—Capecitabine—kidney cancer	0.000108	0.000422	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—kidney cancer	0.000108	0.000421	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—kidney cancer	0.000107	0.000415	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—kidney cancer	0.000107	0.000415	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—kidney cancer	0.000107	0.000415	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—kidney cancer	0.000106	0.000413	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—POMC—kidney cancer	0.000106	0.00826	CbGpPWpGaD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000106	0.000412	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—kidney cancer	0.000105	0.00041	CcSEcCtD
Regadenoson—Dizziness—Capecitabine—kidney cancer	0.000105	0.000408	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	0.000103	0.00803	CbGpPWpGaD
Regadenoson—Anaphylactic shock—Doxorubicin—kidney cancer	0.000102	0.000398	CcSEcCtD
Regadenoson—Vomiting—Capecitabine—kidney cancer	0.000101	0.000392	CcSEcCtD
Regadenoson—Shock—Doxorubicin—kidney cancer	0.0001	0.000391	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—kidney cancer	0.0001	0.00039	CcSEcCtD
Regadenoson—Rash—Capecitabine—kidney cancer	9.99e-05	0.000389	CcSEcCtD
Regadenoson—Dermatitis—Capecitabine—kidney cancer	9.98e-05	0.000388	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—kidney cancer	9.96e-05	0.000388	CcSEcCtD
Regadenoson—Headache—Capecitabine—kidney cancer	9.92e-05	0.000386	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—kidney cancer	9.92e-05	0.000386	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—kidney cancer	9.87e-05	0.000384	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—kidney cancer	9.54e-05	0.000371	CcSEcCtD
Regadenoson—Nausea—Capecitabine—kidney cancer	9.41e-05	0.000366	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—kidney cancer	9.3e-05	0.000362	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—kidney cancer	9.23e-05	0.00036	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—kidney cancer	9.17e-05	0.000357	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—kidney cancer	9.1e-05	0.000354	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—kidney cancer	9.08e-05	0.000353	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Doxorubicin—kidney cancer	8.81e-05	0.000343	CcSEcCtD
Regadenoson—Pain—Doxorubicin—kidney cancer	8.73e-05	0.00034	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—kidney cancer	8.41e-05	0.000328	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—TSC2—kidney cancer	8.4e-05	0.00654	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Doxorubicin—kidney cancer	8.35e-05	0.000325	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—kidney cancer	8.11e-05	0.000316	CcSEcCtD
Regadenoson—Abdominal pain—Doxorubicin—kidney cancer	8.07e-05	0.000314	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—OR4C13—kidney cancer	8.04e-05	0.00627	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—ANXA1—kidney cancer	7.85e-05	0.00612	CbGpPWpGaD
Regadenoson—Hypersensitivity—Doxorubicin—kidney cancer	7.52e-05	0.000293	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—kidney cancer	7.42e-05	0.00578	CbGpPWpGaD
Regadenoson—Asthenia—Doxorubicin—kidney cancer	7.33e-05	0.000285	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—kidney cancer	6.99e-05	0.000272	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—kidney cancer	6.97e-05	0.00543	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LATS1—kidney cancer	6.84e-05	0.00533	CbGpPWpGaD
Regadenoson—Dizziness—Doxorubicin—kidney cancer	6.75e-05	0.000263	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—kidney cancer	6.49e-05	0.000253	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—TSC2—kidney cancer	6.46e-05	0.00503	CbGpPWpGaD
Regadenoson—Rash—Doxorubicin—kidney cancer	6.44e-05	0.000251	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—kidney cancer	6.43e-05	0.00025	CcSEcCtD
Regadenoson—Headache—Doxorubicin—kidney cancer	6.4e-05	0.000249	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—AKAP13—kidney cancer	6.23e-05	0.00485	CbGpPWpGaD
Regadenoson—Nausea—Doxorubicin—kidney cancer	6.06e-05	0.000236	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—RAF1—kidney cancer	5.82e-05	0.00454	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AMER1—kidney cancer	5.82e-05	0.00453	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—kidney cancer	5.76e-05	0.00449	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KIT—kidney cancer	5.7e-05	0.00444	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MTOR—kidney cancer	5.68e-05	0.00443	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKAP13—kidney cancer	5.65e-05	0.00441	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—BRAF—kidney cancer	5.36e-05	0.00418	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—kidney cancer	5.33e-05	0.00416	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ITPR2—kidney cancer	5.29e-05	0.00413	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—JUN—kidney cancer	5.18e-05	0.00403	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	5.05e-05	0.00394	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PTEN—kidney cancer	5.01e-05	0.0039	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—kidney cancer	4.91e-05	0.00383	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CER1—kidney cancer	4.87e-05	0.0038	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GPC3—kidney cancer	4.87e-05	0.0038	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ITPR2—kidney cancer	4.81e-05	0.00375	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—RAF1—kidney cancer	4.48e-05	0.00349	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—RELA—kidney cancer	4.46e-05	0.00347	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ANXA1—kidney cancer	4.44e-05	0.00346	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ERBB2—kidney cancer	4.43e-05	0.00345	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MTOR—kidney cancer	4.37e-05	0.00341	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—kidney cancer	4.2e-05	0.00327	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SFRP2—kidney cancer	4.14e-05	0.00323	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1B—kidney cancer	4.1e-05	0.0032	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ANXA1—kidney cancer	4.03e-05	0.00314	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK1—kidney cancer	3.99e-05	0.00311	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—POMC—kidney cancer	3.85e-05	0.003	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PTEN—kidney cancer	3.78e-05	0.00294	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—kidney cancer	3.77e-05	0.00294	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—kidney cancer	3.46e-05	0.0027	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TP53—kidney cancer	3.42e-05	0.00266	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKAP13—kidney cancer	3.34e-05	0.0026	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP2—kidney cancer	3.34e-05	0.0026	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK3—kidney cancer	3.23e-05	0.00251	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK1—kidney cancer	3.07e-05	0.00239	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRB7—kidney cancer	3.06e-05	0.00238	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KRAS—kidney cancer	2.9e-05	0.00226	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ITPR2—kidney cancer	2.84e-05	0.00221	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CA—kidney cancer	2.66e-05	0.00208	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CTNNA1—kidney cancer	2.57e-05	0.00201	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HSPB1—kidney cancer	2.56e-05	0.002	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EIF4EBP1—kidney cancer	2.56e-05	0.002	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PSMD7—kidney cancer	2.38e-05	0.00185	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TSC1—kidney cancer	2.38e-05	0.00185	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ANXA1—kidney cancer	2.38e-05	0.00185	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FLT1—kidney cancer	2.31e-05	0.0018	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—POMC—kidney cancer	2.17e-05	0.00169	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PAK1—kidney cancer	2.14e-05	0.00167	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JUNB—kidney cancer	2.14e-05	0.00167	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—POMC—kidney cancer	1.97e-05	0.00154	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF2—kidney cancer	1.75e-05	0.00136	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN2B—kidney cancer	1.74e-05	0.00136	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1R—kidney cancer	1.69e-05	0.00132	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RAF1—kidney cancer	1.63e-05	0.00127	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—IL2—kidney cancer	1.61e-05	0.00125	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL2—kidney cancer	1.46e-05	0.00114	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIF1A—kidney cancer	1.39e-05	0.00108	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TSC2—kidney cancer	1.39e-05	0.00108	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KDR—kidney cancer	1.33e-05	0.00104	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APC—kidney cancer	1.23e-05	0.000955	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KIT—kidney cancer	1.23e-05	0.000955	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAPK3—kidney cancer	1.17e-05	0.000914	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—POMC—kidney cancer	1.17e-05	0.000909	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BRAF—kidney cancer	1.15e-05	0.000897	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAPK1—kidney cancer	1.12e-05	0.00087	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CA—kidney cancer	1.07e-05	0.000831	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KRAS—kidney cancer	1.05e-05	0.000822	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CA—kidney cancer	9.69e-06	0.000755	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RAF1—kidney cancer	9.61e-06	0.000749	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RELA—kidney cancer	9.57e-06	0.000746	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB2—kidney cancer	9.51e-06	0.000741	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MTOR—kidney cancer	9.39e-06	0.000732	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1B—kidney cancer	8.81e-06	0.000687	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL2—kidney cancer	8.62e-06	0.000672	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCND1—kidney cancer	8.4e-06	0.000655	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JUN—kidney cancer	8.39e-06	0.000654	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CTNNB1—kidney cancer	8.32e-06	0.000649	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTEN—kidney cancer	8.11e-06	0.000632	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—kidney cancer	7.33e-06	0.000571	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK3—kidney cancer	6.93e-06	0.00054	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—kidney cancer	6.74e-06	0.000525	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK1—kidney cancer	6.59e-06	0.000514	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KRAS—kidney cancer	6.23e-06	0.000485	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CA—kidney cancer	5.72e-06	0.000446	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TP53—kidney cancer	5.54e-06	0.000431	CbGpPWpGaD
